

# **Specificity and Properties of Anti-HLA Antibodies Associated with Renal Allograft Rejection**

**Hooi Sian Eng**

Bachelor of Biomedical Science (Hon)  
Master of Medical Science

A thesis submitted for the degree of PhD

School of Medicine  
Faculty of Health Science  
University of Adelaide, South Australia

February 2009

# i. Contents

i.	Contents .....	2
ii.	List of Tables .....	6
iii.	List of Figures .....	8
iv.	Summary .....	9
v.	Dedication.....	11
vi.	Acknowledgements .....	12
vii.	Declaration.....	13
viii.	Thesis Structure .....	14
ix.	Abbreviations .....	15
x.	Publications .....	17
xi.	Presentations.....	19
xii.	Awards.....	22
1	Chapter 1 Literature Review.....	23
1.1	Overview of Human Major Histocompatibility Complex (MHC) – Gene Discovery.....	24
1.1.1	Chronology of HLA Discovery .....	25
1.2	Genetics of MHC.....	25
1.2.1	Evolution of MHC Genes .....	28
1.2.2	MHC Gene Polymorphism.....	29
1.3	Human Leukocyte Antigen (HLA) System .....	31
1.3.1	HLA Gene Inheritance and Frequency.....	33
1.3.2	HLA Class I, II and III Regions .....	33
1.4	Nomenclature .....	35
1.5	Structure of HLA Molecules .....	37
1.5.1.1	HLA Peptide-Binding Grooves.....	40
1.5.2	HLA Epitopes.....	42
1.5.3	HLA Expression.....	43
1.6	Roles of HLA Molecules.....	43
1.6.1	Antigen Presentation .....	43
1.6.1.1	Endogenous Presentation Pathway.....	43
1.6.1.2	Exogenous Presentation Pathway.....	45
1.6.2	T-cell Receptor Repertoire Selection .....	47
1.6.3	Regulation of NK Cell Activity.....	50
1.7	Significance of HLA in Renal Transplantation.....	52
1.7.1	Mechanism of Renal Allograft Rejection .....	52
1.7.1.1	Isolated MHC Class I Disparity .....	53
1.7.1.2	Isolated MHC class II Disparity .....	56
1.7.1.3	MHC Class I and II Disparity.....	58
1.8	Pre-transplantation HLA Antibody Detection and Crossmatching .....	60
1.8.1	Negative T-cells / Positive B-cells Crossmatches (TN/BP).....	60
1.8.2	Crossmatch: Current Serum Negative / Historic Serum Positive (CN/HP) .....	61
1.8.3	Crossmatch: DTT-Reducible Positivity.....	63
1.9	Post-transplantation Monitoring – Donor-Specific Antibodies.....	64
1.10	MHC Class I Chain Related (MIC) Genes: MICA and MICB .....	65
1.11	HLAMATCHMAKER – Amino Acid Triplet Program .....	66
1.12	Antibody Detection Techniques .....	67
1.12.1	Complement-dependent Lymphocytotoxicity Assay .....	67
1.12.2	Flow Cytometry.....	68
1.12.3	Solid Phase ELISA .....	69
1.12.4	Solid Phase Luminex® .....	69
1.12.5	Method Comparison .....	70
2	Chapter 2 Materials & Methods.....	72
2.1	HLA Antigen Typing .....	73
2.1.1	Dynabead® T-cell Isolation .....	73
2.1.2	Dynabead® B-cell Isolation .....	73
2.1.3	Serology HLA Antigen Typing .....	74

2.1.4	DNA Quantitation.....	74
2.1.5	Gel Electrophoresis .....	74
2.1.6	Visualization of PCR Product .....	75
2.1.7	Sequence Base Typing .....	75
2.1.7.1	Prepare PCR Mixture.....	75
2.1.7.2	PCR Product Visualization.....	77
2.1.7.3	AMPure PCR Purification .....	77
2.1.7.4	ABI Big Dye Terminator Ready Reaction Kit.....	78
2.1.7.5	CleanSEQ Dye Terminator Removal.....	79
2.1.8	Luminex® Single Stranded Oligonucleotide (SSO) HLA Typing.....	80
2.1.8.1	Prepare PCR Mixture.....	80
2.1.8.2	Visualization of PCR Product.....	81
2.1.8.3	Hybridisation .....	81
2.2	Crossmatch .....	82
2.2.1	Direct Crossmatch .....	82
2.2.2	DTT Crossmatch .....	83
2.3	Anti-HLA Antibodies Screening.....	84
2.3.1	SeraClean.....	84
2.3.2	Luminex® Screen and PRA .....	84
2.3.3	Luminex® Single Antigen Bead.....	85
2.3.4	Luminex® Single Antigen Beads – Anti-HLA antibodies IgG subclass .....	85
2.4	Database .....	86
2.4.1	National Organ Matching System (NOMS) .....	86
2.5	Statistics .....	88
2.6	Reagent Preparation .....	89
2.7	Equipments .....	94
2.8	Kits .....	95
2.9	Chemicals.....	95
2.10	Consumables .....	96
3	Chapter 3 Clinical Relevance of A positive B-cell Crossmatch in Renal transplantation.....	97
3.1	Introduction.....	98
3.2	Objectives.....	99
3.3	Materials and Methods.....	100
3.3.1	Study Cohort.....	100
3.3.2	HLA Typing.....	100
3.3.3	Screening for Autoantibodies .....	100
3.3.4	Luminex® .....	101
3.3.5	Antibody Specificity .....	101
3.3.6	Clinical Data .....	101
3.3.7	Statistics .....	102
3.4	Results .....	103
3.4.1	Characteristics of Patients with T–B+ crossmatch.....	103
3.4.2	Luminex® Specificity of Anti B-cell Antibodies.....	106
3.4.3	Early Graft Rejection .....	106
3.4.3.1	Correlation of T–B+ and Early Graft Rejection .....	107
3.4.3.2	Correlation of Early Graft Rejection and Antibody Specificity in T–B+ .....	109
3.4.4	Graft Function at 6, 12 and 36 month Post-transplantation .....	114
3.4.5	Graft Survival.....	116
3.4.5.1	Significance of T–B+ in Graft Survival .....	116
3.4.5.2	Correlation of Antibody Specificity in T–B+ with Graft Survival .....	116
3.4.6	Historic Positive B-cell Crossmatch.....	121
3.4.7	BXM as A Predictor of Graft Failure in 5 years Post-transplantation .....	127
3.5	Discussion .....	128
4	Chapter 4 Anti-HLA Antibodies and Risk Factors Associated with Transplant Glomerulopathy .....	132
4.1	Introduction.....	133
4.2	Objectives.....	134
4.3	Materials and Methods.....	134

4.3.1	Study Cohorts .....	134
4.3.2	HLA Typing .....	135
4.3.3	Detection of Anti-HLA Antibodies .....	135
4.3.4	Clinical Data – ANZDATA Analysis .....	135
4.3.5	Statistics .....	136
4.4	Results .....	137
4.4.1	Univariate Risk Factors .....	137
4.4.1.1	Demographic Comparison .....	137
4.4.1.2	Immunosuppression.....	140
4.4.2	Early Graft Rejection .....	142
4.4.3	Significance of Anti-HLA Antibodies in Transplant Glomerulopathy .....	144
4.4.3.1	CDC Class I PRA defined Presensitization .....	144
4.4.3.2	Luminex <sup>®</sup> defined Presensitization .....	144
4.4.3.3	Pre-transplant DSA as A Risk Factor of TG .....	146
4.4.3.4	<i>De novo</i> DSA Predict TG.....	146
4.4.4	Multivariate Analysis.....	148
4.4.5	DSA as A Predictor of TG.....	150
4.4.5.1	Time to Biopsy .....	150
4.4.5.2	Association of TG and Graft Survival.....	151
4.4.5.3	Pre-transplant DSA Associated with Early TG Development .....	156
4.4.5.4	Significance of DSA in TG Progression .....	157
4.4.6	DSA are Predictive for Graft Loss in TG .....	159
4.5	Discussion .....	161
5.	Chapter 5 A Retrospective Study of B-cell Crossmatch with Luminex <sup>®</sup> Technology in Well-Matched Highly Sensitized Patients from The Australian National Renal Exchange Programme (ANREP)...	165
5.1	Introduction.....	166
5.2	Objectives.....	167
5.3	Materials and Methods.....	168
5.3.1	Study Cohort.....	168
5.3.2	Crossmatch .....	169
5.3.3	HLA Typing.....	170
5.3.4	Luminex <sup>®</sup> Antibody Analysis.....	170
5.3.5	Clinical Data .....	171
5.3.6	Statistics .....	171
5.4	Results .....	171
5.4.1	Characteristics of Study Cohort.....	171
5.4.2	Graft Outcomes of Highly Sensitized Patients .....	176
5.4.2.1	Graft Rejection .....	176
5.4.2.2	Graft Function .....	178
5.4.2.3	Graft Survival .....	179
5.4.3	Predictive Value of B-cell Crossmatch in Highly Sensitized Patients .....	181
5.4.3.1	Prevalence of Positive B-cell Crossmatch.....	181
5.4.3.2	Characteristics of Patients with Positive B-cell Crossmatch .....	181
5.4.3.3	Correlation of B-cell Crossmatch and Graft Rejection.....	185
5.4.3.4	Graft function B-cell Crossmatch and Graft Function .....	187
5.4.3.5	Correlation of B-cell Crossmatch and Graft Survival.....	188
5.4.4	Predictive Value of Luminex <sup>®</sup> defined Donor-specific Antibodies .....	190
5.4.4.1	Presence of Donor-specific Antibodies.....	190
5.4.4.2	Specificity of DSA defined by Luminex <sup>®</sup> .....	194
5.4.4.3	Correlation of DSA and Graft Rejection.....	196
5.4.4.4	Correlation of DSA and Graft Function .....	198
5.4.4.5	Correlation of Luminex <sup>®</sup> defined DSA and Graft Survival.....	199
5.4.5	Luminex <sup>®</sup> defined DSA in B-cell Crossmatches .....	201
5.4.5.1	Correlation of Luminex <sup>®</sup> defined DSA and BXM with Graft Rejection .....	202
5.4.5.2	Multivariate analysis of BXM and Luminex <sup>®</sup> defined DSA in predicting rejection.....	202
5.5	Discussion .....	204

6	Chapter 6 Discussion .....	209
6.1	Significance of Preformed Anti-HLA Antibodies Detected by B-cell Crossmatch.....	210
6.1.1	Antibodies Causing Positive B-cell Crossmatches and Correlation with Graft Outcomes...	214
6.2	Luminex <sup>®</sup> Defined Donor-specific Antibodies as A Predictor of Graft Outcomes .....	214
6.1.2	Solid Phase Antibody Analysis: Virtual Crossmatch .....	215
6.2.2.1	Prediction of Flow Crossmatch Outcomes by Luminex <sup>®</sup> Assays.....	216
6.2.2.2	Improved Transplant Rate by Defining Acceptable Mismatches .....	219
6.2.2.3	Cost-Effectiveness of Solid Phase Assays Virtual Crossmatch .....	219
6.2.2.4	Possible Weaknesses of Solid Phase Assays Virtual Crossmatch .....	220
6.1.3	Luminex <sup>®</sup> Antibody Analysis and Luminex <sup>®</sup> Lysate Crossmatch .....	221
6.1.4	DSA in Transplant Glomerulopathy – Significance of Post-transplant Monitoring .....	222
6.3	Summary of Conclusions .....	223
	References .....	225
	Appendix .....	243

## ii. List of Tables

### Chapter 2

Table 2.1.1: Preparation of PCR Mixture for Sequence Base Typing .....	75
Table 2.1.2: PCR conditions for Sequence Base Typing.....	76
Table 2.1.3: Conditions of sequencing amplification.....	79
Table 2.1.5: Preparation of PCR mixtures for Luminex <sup>®</sup> SSO .....	80
Table 2.1.6: Condition of PCR amplification for Luminex <sup>®</sup> SSO .....	81
Table 2.1.7: Hybridisation steps for Luminex <sup>®</sup> SSO .....	82

### Chapter 3

Table 3.4.1: Descriptive statistics of cohorts by the result of B-cell crossmatching .....	104
Table 3.4.2: Immunosuppression in T-B- and T-B+ groups .....	105
Table 3.4.3: Prevalence of cellular, vascular and glomerular rejection in All grafts, T-B- and T-B+ groups .....	108
Table 3.4.4: Graft rejection at 6 months according to the antibody specificity in T-B+ .....	110
Table 3.4.5: Risk of cellular rejection according to the antibody specificity in T-B+ .....	111
Table 3.4.6: Risk of vascular rejection according to the antibody specificity in T-B+ .....	112
Table 3.4.7: Risk of glomerular rejection according to the antibody specificity in T-B+ .....	113
Table 3.4.8: eGFR at 6, 12 and 36 months by B-cell crossmatch and antibody specificity, .....	115
Table 3.4.9: Graft survival rates and hazard ratios for graft loss by antibody specificity .....	118
Table 3.4.10: Prevalence of cellular, vascular and glomerular rejection in T-B+ subgroups .....	122
Table 3.4.11: Odds ratios of graft rejection at 6 months in T-B+ subgroups .....	123
Table 3.4.12: eGFR at 6, 12 and 36 months post-transplant in T-B+ subgroups .....	124
Table 3.4.13: Graft survival rates and hazard ratios for graft loss in T-B+ subgroups.....	125
Table 3.4.14: Graft outcomes at 5 years post-transplant.....	127

### Chapter 4

Table 4.4.1: Descriptive statistics of cohort and univariate analyses of risk factor of TG.....	138
Table 4.4.2: Immunosuppressants at induction and prior to diagnosis of TG.....	141
Table 4.4.3: Cellular, vascular and glomerular rejection as a risk factor of TG .....	143
Table 4.4.4: Univariate effects of HLA presensitization, defined by CDC or Luminex <sup>®</sup> techniques, in the development of TG .....	145
Table 4.4.5: Univariate effects of anti-HLA antibodies in the development of TG .....	147
Table 4.4.6: In multiple regression analysis, DSA was the only independent predictor of TG. ....	149
Table 4.4.7: Graft survival rates in patients with TG, according to antibody specificity .....	152
Table 4.4.8: Graft survival and risk of graft loss in TG patients, according to antibody specificity, in 20 years of follow up .....	153

### Chapter 5

Table 5.3.1: Patient recruitment.....	168
Table 5.4.1: Descriptive statistics of study cohort, compared to all other grafts transplanted within the same period in participating centres .....	173
Table 5.4.2: Immunosuppressants at induction .....	175
Table 5.4.3: Risk of cellular, vascular and glomerular rejection in highly sensitized patients .....	177
Table 5.4.4: Graft function, eGFR, of highly sensitized patients.....	178
Table 5.4.5: Total graft survival rates in highly sensitized patients, compared to all grafts .....	180
Table 5.4.6: Demographics of T-B- and T-B+ groups .....	182
Table 5.4.7: Immunosuppressants at induction for T-B- and T-B+ groups .....	184
Table 5.4.8: Correlations of T-B+ with cellular, vascular and glomerular rejection.....	186
Table 5.4.9: Comparison of graft function (MDRD eGFR) between T-B- and T-B+ groups.....	187
Table 5.4.10: Correlation of T-B+ and total graft survival .....	189
Table 5.4.11: Demographics of DSA and Non-DSA groups .....	191
Table 5.4.12: Immunosuppressants at induction for DSA and Non-DSA groups .....	193
Table 5.4.13: Correlations of DSA with cellular, vascular and glomerular rejection .....	197
Table 5.4.14: Comparison of graft function (MDRD eGFR) between Non-DSA and DSA groups .....	198
Table 5.4.15: Correlation of DSA and total graft survival.....	200
Table 5.4.16: BXM results and specificity of DSA in highly sensitized patients .....	201
Table 5.4.17: Independent predictors of graft rejection .....	203

Chapter 6

Table 6.1.1: A summary of studies investigated clinical significance of positive BXM in renal transplantation.....212

Table 6.2.1: A review of clinical significance of low titer DSA detected by Luminex® or Flow crossmatch in sera with negative CDC / AHG-CDC.....218

### iii. List of Figures

#### Chapter 1

Figure 1.2.1: Human MHC gene map .....	27
Figure 1.2.2: Timescale of MHC evolution .....	29
Figure 1.3.1: The number of antigens and alleles from 1968 to September 2008. ....	32
Figure 1.3.2: HLA gene map illustrates clustering of immune system .....	34
Figure 1.5.1: Structure of HLA class I molecules .....	38
Figure 1.5.2: Ribbon structure of class I peptide binding groove .....	38
Figure 1.5.3: Structure of HLA class II molecule .....	39
Figure 1.5.4: Peptide in HLA peptide-binding groove .....	40
Figure 1.5.5: Amino acid pockets in the floor of binding groove determine the binding of peptide .....	41
Figure 1.5.6: HLA molecule epitopes .....	42
Figure 1.6.1: Roles of peptide loading complex in MHC class I assembly and peptide loading. ....	44
Figure 1.6.2: Endogenous peptide presentation pathway .....	45
Figure 1.6.3: Exogenous antigen presentation pathway .....	46
Figure 1.6.4: Positive and negative selection of T-cell receptor repertoire .....	49
Figure 1.6.5: Regulation of NK activity by HLA class I molecules .....	51
Figure 1.7.1: Effector mechanisms of rejection in graft carrying mismatched HLA class I antigen. ....	55
Figure 1.7.2: Effector mechanism of rejection in graft carrying mismatched HLA class II antigens. ....	57
Figure 1.7.3: Effector mechanisms of rejection in graft carrying mismatched HLA class I and class II antigens .....	59

#### Chapter 3

Figure 3.4.1: T–B+ as a group was not associated with inferior graft survival .....	119
Figure 3.4.2: Graft survival according to antibody specificity in T–B+ .....	120
Figure 3.4.3: Significance of DSA class in graft survival .....	121
Figure 3.4.4: 5 years graft survival in T–B+ subgroups stratified by peak/current status .....	126

#### Chapter 4

Figure 4.4.1: Cumulative graph for biopsy events in relation to time post-transplantation .....	150
Figure 4.4.2: Graft survival in the controls and patients .....	154
Figure 4.4.3: Graft survival before and after diagnosis of TG .....	155
Figure 4.4.4: Cumulative TG diagnosis events in relation to time post-transplant, according to presence of DSA .....	156
Figure 4.4.5: Graft survival in patients with TG according to presence of DSA .....	158
Figure 4.4.6: Graft survival in TG subgroups, compared to the control group .....	160

#### Chapter 5

Figure 5.4.1: Graft function of highly sensitized patients, compared to all grafts .....	178
Figure 5.4.2: Total graft survival of highly sensitized patients, compared to all grafts .....	179
Figure 5.4.3: Correlation of graft function and BXM .....	187
Figure 5.4.4: Significance of positive BXM in relation to graft survival .....	188
Figure 5.4.5: Specificity of HLA class I donor-specific antibodies in highly sensitized patients .....	195
Figure 5.4.6: Specificity of HLA class II donor-specific antibodies in highly sensitized patients .....	195
Figure 5.4.7: A trend of poor graft function in DSA group within 1 year post-transplant .....	198
Figure 5.4.8: Graft survival in the presence of DSA .....	199

## iv. Summary

Identification of the complement C4d fragment in peritubular capillaries as a specific marker for antibody mediated rejection in renal transplantation revealed the critical role of antibodies in graft survival. In this thesis, I document the design and findings of studies performed to investigate the clinical impact of anti-HLA antibodies present before and/or after transplantation.

Over time, the detection techniques for anti-HLA antibodies has evolved from the less sensitive complement-dependent lymphocytotoxicity (CDC) crossmatching (XM) to more sensitive solid phase assays such as Luminex<sup>®</sup>. Studies have been conducted to compare the predictive value of different antibody detection techniques.

The first result chapter presents antibody specificity in positive CDC B-cell crossmatch (BXM), analysed with highly specific Luminex<sup>®</sup> assays. The study also investigates the predictive value of BXM in the general transplant population. I found that donor-specific anti-HLA antibodies (DSA) are only present in one third of positive BXM and are associated with poor outcomes. The novel finding is that >80% of the DSA detected by BXM are complement-fixing IgG<sub>1</sub> and IgG<sub>3</sub> subclasses.

Transplant glomerulopathy (TG) is type of chronic renal graft rejection. The pathogenesis of TG is unclear. In the second result chapter, I report risk factors and involvement of anti-HLA antibodies in the development of TG. This study shows that glomerular rejection, delayed graft function, HLA presensitization and DSA have a univariate effect on TG development. Multivariate analysis revealed that DSA are an independent predictor of TG, after adjustment for other risk factors.

I have further investigated the role of BXM in a unique, well-matched, highly sensitized patient group transplanted under the national renal exchange programme. I compared Luminex<sup>®</sup> antibody analysis with BXM in predicting transplant outcomes. In highly sensitized patients, DSA are found in two thirds of positive BXM. In univariate analyses, BXM is associated with humoral rejection whereas DSA defined by Luminex<sup>®</sup> are associated with total and all rejection types. The major finding is that, by multivariate analysis, DSA defined by Luminex<sup>®</sup> are an independent predictor of total and humoral rejection, but BXM are not. These interesting findings are reported in the third result chapter.

Studies reported in this thesis define the clinical significance of anti-HLA antibodies in renal transplant outcomes. Method comparison studies provide useful information on antibody specificity and their impact on graft survival. Collectively, a better understanding of alloantibodies associated with graft rejection and limitation of antibody detection methods may facilitate donor selection and choice of immunosuppressants, and consequently improve transplant outcomes.

## **v. Dedication**

*For my father Kheng Choo, mother Sew Kee, siblings Hooi Ling, Inn Soo, Hooi Ping, Soo Tchien, Chuen Sin, Sin Zheng and husband Lee Khuan.*

## **vi. Acknowledgements**

A thesis, with multiple research studies and high quality collaboration, such as this can only be completed with a brilliant and exceptional supportive team of supervisors, collaborators, and team assistance. I have had the privilege to be supervised by Professor Graeme Russ, Dr. Toby Coates and, and Dr. Peter Bardy, without whom, my study would not be possible. I am so honoured and most grateful to have the opportunity to work in such an amazing team environment. My most heartfelt thanks for all your professional advice, your guidance, and unwavering support.

To my wonderful collaborators, of whom I am most appreciative and honoured to have work with. Firstly Dr. Brian Tait (Royal Melbourne Hospital) and his team for their involvement in the National B-cell Cross-match Study, through data and serum collection, and presentation and further learning and networking opportunities within the local and international research and clinical community. Many thanks, it is such an honour to work with such a gracious and encouraging individual.

My thanks to all the participating hospitals, and tissue-typing laboratories, who have collected serum and data for contribution to this research. Your professional accurate and timely support has made this research possible.

To the ANZDATA team who has worked tirelessly, sometimes with unimaginable deadlines, and overtime hours, for such high quality data analysis. Special thanks to Ms. Hannah Dent, Mr. Brian Livingstone, and Dr. Sean Chang.

Thank you to my colleagues at the South Australian Tissue Typing Laboratory (Pirie Street, Adelaide) of National Transplantation Immunology Services, Australian Red Cross Blood Service, and The Queen Elizabeth Hospital's Transplantation Immunology Team. The support, assistance and encouragement, and positive learning and working environments they have provided have been enjoyable and exceptional, and fundamental to my completion of this work.

Finally I would like to thank the organisations who have made many educational, financial and facility contributions, to this thesis possible. Thank you especially to the National Transplantation Services of Australian Red Cross Blood Service, the Australian Department of Education, Science and Technology, and University of Adelaide, and Department of Nephrology and Transplantation services Queen Elizabeth Hospital, Woodville, South Australia for their support.

## **vii. Declaration**

This work contains no material which has been accepted for the award of any other degree or diploma in any university or other tertiary institution and, to the best of my knowledge and belief, contains no material previously published or written by another person, except where due reference has been made in the text.

I give consent to this copy of my thesis when deposited in the University Library, being made available for loan and photocopying, subject to the provisions of the Copyright Act 1968.

I also give permission for the digital version of my thesis to be made available on the web, via the University's digital research repository, the Library catalogue, the Australasian Digital Theses Program (ADTP) and also through web search engines, unless permission has been granted by the University to restrict access for a period of time.

-----  
Hooi Sian Eng

## **viii. Thesis Structure**

Chapter 1 is a review of Human Leukocyte Antigen (HLA) system consists of the genetics, structures and functions of HLA molecules. It also describes role of HLA antigen in renal graft rejection, and current tissue typing and antibody detection techniques.

Chapter 2 contains the materials and methods used to perform the studies described in Chapter 3 to 5. The steps of tissue typing and Luminex<sup>®</sup> assays and reagent preparation are documented. Statistical tests for patient demographics and transplant outcomes comparisons are recorded in this chapter.

This thesis consists of three studies performed on patients with different transplant characteristics. The first study investigated the clinical significance of positive B-cell crossmatch in an Australian renal transplant population using Luminex<sup>®</sup> assays. This study also examined the specificity of antibody causing positive B-cell crossmatch and correlation with renal transplant outcomes. The design and results of the study are described in Chapter 3.

The pathogenesis of transplant glomerulopathy remains unknown. The second study described in Chapter 4 reported the involvement of anti-HLA antibodies in development of transplant glomerulopathy. This study also indentified the influence of anti-HLA antibodies on the progression of transplant glomerulopathy.

The Australia National Renal Exchange Programme commenced in October 2004 to improve the HLA antigen matching and transplant rate for highly sensitized patients. Chapter 5 reported the overall performance of patients transplanted under this programme in comparison to general transplant population. Clinical predictive value of B-cell crossmatch and Luminex<sup>®</sup> antibody analysis in highly sensitized patients were also compared.

Chapter 6 brings together the findings of the studies reported in Chapter 3 to 5, and examined the uses of BXM and Luminex<sup>®</sup> assays in current tissue typing protocol. The results are compared to previous studies and appropriate comments are included.

A list of references and then an appendix are attached after Chapter 6. The appendix consists of the published journal article that has arisen from the findings presented in this thesis.

## ix. Abbreviations

AAT	amino acid triplets
ADCC	antibody-mediated cell cytotoxicity
ELISA	enzyme-linked immunosorbent assay
AHR	acute humoral rejection
APC	antigen-presenting cells
BXM	B-Cell crossmatch
CAN	chronic allograft nephropathy
CDC	complement-dependent lymphocytotoxicity
CN/HP	current serum negative/ historic serum positive
CNX	calnexin
CREGs	cross-reactive groups
CRT	chaperone calreticulin
CTLRs	C-type lectin receptors
cTLs	cytotoxic T-lymphocytes
DISC	death-inducing signal complex
DS/SAPE	dilution Solution/PE Streptavidin
DSA	donor specific antibodies
DTH	delayed hypersensitivity reaction
DTT	dithiothreitol
EPO	eosinophil peroxidase
ER	endoplasmic reticulum
ERAAP or ERAP 1	ER associated aminopeptidase
ERp57	thiol oxidoreductase
FasL	Fas-ligand
Fc-receptors	fragment , crystallisable
H	histocompatibility
HLA	human leukocyte antigen
IFN	interferon
IL	interleukin
IMGT	ImMunoGeneTics
IR	Immune Response
ITIMs	immunoreceptor tyrosine-based inhibitory motifs
KIR	killer like receptor
LD	linkage disequilibrium
Li	Invariant chain
MESF	Molecules of Equivalent Soluble Fluorochrome
MFI	Median Fluorescence Intensity
MHC	Major Histocompatibility complex
MIC	MHC class 1 chain-related genes
MMF	mycophenolate mofetil
Mya	million years ago
NK	natural killer

NO	nitric oxide
PBS	phosphate buffered saline
PBS/citrate	trisodium citrate
PFD	probability of finding a donor
RSA	recurrent spontaneous abortions
TAP	transporter associated with antigen processing
TCR	T-cell receptor
TG	transplant glomerulopathy
TH1	T helper
TN/BP	negative T-cells/positive B-cells crossmatches
TNF	tumour necrosis factor
TPSN	Tapasin
TXM	T-cell crossmatch
UNOS	United Network for Organ Sharing Registry
XM	crossmatching

## **x. Publications**

1. HS Eng, G Bennett, I Humphreys, E. Tsiopelas, M Lake, SH Chang, P Bardy, PTH Coates and G. Russ. Luminex<sup>®</sup> Investigation: Low titer HLA donor-specific antibodies in positive B-cell crossmatches predict late graft loss. *Nephrology* 2007:Supp 1;A19.
2. HS Eng, G Bennett, I Humphreys, E. Tsiopelas, M Lake, SH Chang, P Bardy, PTH Coates and G. Russ. Luminex<sup>®</sup> Investigation of Positive B-cell Crossmatches: low titer HLA donor-specific antibodies associated with inferior outcomes. *Human Immunology* 2007:68 Supp 1:S31.
3. HS Eng, G Bennett, I Humphreys, E. Tsiopelas, M Lake, SH Chang, P Bardy, PTH Coates and G. Russ. Anti-HLA donor-specific antibodies detected in positive B-cell crossmatches by Luminex<sup>®</sup> predict late graft loss. *American Journal of Transplantation* 2008 8(11):2335-42.
4. Hooi Sian Eng, Scott Campbell, Graeme Russ, P. Toby H. Coates, Peter Bardy, Greg Bennett, Sean Chang, Brian Tait, On behalf of the Renal Transplant Advisory Committee (RTAC). A retrospective study of B-cell crossmatch with Luminex<sup>®</sup> technology in well-matched highly sensitized patients from the AUSTRALIAN interstate exchange. *Nephrology* 2008:13;A112.
5. Hooi Sian Eng, Greg Bennett, Eleni Tsiopelas, Sean Chang, Peter Bardy, Graeme Russ, P. Toby H. Coates. Alloantibody involvement and risk factors in transplant glomerulopathy. *Nephrology* 2008:13;A99.
6. Hooi Sian Eng, Scott Campbell, Graeme Russ, P. Toby H. Coates, Peter Bardy, Greg Bennett, Sean Chang, Brian Tait, On behalf of the Renal Transplant Advisory Committee (RTAC). Predictive value of B-cell crossmatch and Luminex<sup>®</sup> antibody analysis in well-matched highly sensitized patients from the Australian National Interstate Exchange (ANIE). *Human Immunology* 2008:69;S13.

7. Hooi Sian Eng, Greg Bennett, Eleni Tsiopelas, Sean Chang, Peter Bardy, Graeme Russ, P. Toby H. Coates. Donor specific anti-HLA antibodies in transplant glomerulopathy. *Human Immunology* 2008;69;S109.
8. Hooi Sian Eng, Greg Bennett, Peter Bardy, Patrick Coghlan, Graeme R. Russ, P. Toby H. Coates. Clinical significance of anti-HLA antibodies detected by Luminex<sup>®</sup>: Enhancing the interpretation of CDC-BXM and important post-transplant monitoring tools. *Human Immunology* 2009 *In press*.

## **xi. Presentations**

1. HS Eng, G Bennett, I Humphreys, E. Tsiopelas, M Lake, SH Chang, P Bardy, PTH Coates and G. Russ. Clinical relevance of a positive B-cell crossmatch on renal transplantation: A single centre study. The Queen Elizabeth Hospital Research Day 20 October 2006, Adelaide, Australia.
2. HS Eng, G Bennett, I Humphreys, E. Tsiopelas, M Lake, SH Chang, P Bardy, PTH Coates and G. Russ. Analysis of the specificity and properties of alloantibodies associated with rejection of renal transplant. The 3<sup>rd</sup> International Summer School on Immunogenetics 17-21 November 2006, Bangkok, Thailand.
3. HS Eng, G Bennett, I Humphreys, E. Tsiopelas, M Lake, SH Chang, P Bardy, PTH Coates and G. Russ. B-cell crossmatching and kidney allograft outcomes in cadaveric transplant recipients. The 30<sup>th</sup> Annual Scientific Meeting of The Australasia and South East Asia Tissue Typing Association 22-25 November 2006, Chiang Mai, Thailand.
4. HS Eng, G Bennett, I Humphreys, E. Tsiopelas, M Lake, SH Chang, P Bardy, PTH Coates and G. Russ. Luminex<sup>®</sup> investigation of positive B-cell crossmatches in renal transplantation. The 31<sup>st</sup> Annual Scientific Meeting of The Transplantation Society of Australia and New Zealand 28-30 March 2007, Canberra, Australia.  
*TSANZ Young Investigator Award 2007*
5. HS Eng, G Bennett, I Humphreys, E. Tsiopelas, M Lake, SH Chang, P Bardy, PTH Coates and G. Russ. Luminex<sup>®</sup> Investigation: Low Titer HLA Donor-specific Antibodies in Positive B-cell Crossmatches Predict Late Graft Loss. The 43<sup>rd</sup> Annual Scientific Meeting of The Australia and New Zealand Society of Nephrology (ANZSN) 8-12 September 2007, Queensland, Australia.  
*Kidney Health Australia (KHA) Award for The Best Clinical Science Presentation*

6. HS Eng, G Bennett, I Humphreys, E. Tsiopelas, M Lake, SH Chang, P Bardy, PTH Coates and G. Russ. Luminex<sup>®</sup> Investigation of Positive B-cell Crossmatches: Low Titer HLA Donor-specific Antibodies Associated with Inferior Outcomes. The 33<sup>rd</sup> Annual Meeting of American Society For Histocompatibility and Immunogenetics (ASHI) 8-12 October 2007, Minnesota, USA.
7. HS Eng, G Bennett, I Humphreys, E. Tsiopelas, M Lake, SH Chang, P Bardy, PTH Coates and G. Russ. Low Titer Donor-specific Antibodies in Positive B-cell Crossmatches Predict Late Graft Loss. The 31<sup>st</sup> Annual Scientific Meeting of Australasia and South East Asia Tissue Typing Association 15-18 November 2008, Perth, Australia.
8. Hooi Sian Eng, Scott Campbell, Graeme Russ, P. Toby H. Coates, Peter Bardy, Greg Bennett, Sean Chang, Brian Tait, On behalf of the Renal Transplant Advisory Committee (RTAC). Clinical significance of B-cell positive crossmatches and Luminex<sup>®</sup> defined donor-specific antibodies in well-matched highly sensitized patients from the AUSTRALIAN interstate exchange.  
The XXII International Congress of The Transplantation Society 10-14 August 2008, Sydney, Australia.
  - *Top 10 Abstracts Young Investigation Award of The XXII International Congress of The Transplantation Society 10-14 August 2008, Sydney, Australia.*
  - *Nominee for The President's Award of The Transplantation Society of Australia and New Zealand (TSANZ).*
  - *TSANZ Young Investigator Award*
  - *Amgen Young Investigator Award*

9. Hooi Sian Eng, Greg Bennett, Eleni Tsiopelas, Sean Chang, Peter Bardy, Graeme Russ, P. Toby H. Coates. Risk factors and associations with alloantibodies in transplant glomerulopathy. The XXII International Congress of The Transplantation Society 10-14 August 2008, Sydney, Australia.
10. Hooi Sian Eng, Scott Campbell, Graeme Russ, P. Toby H. Coates, Peter Bardy, Greg Bennett, Sean Chang, Brian Tait, On behalf of the Renal Transplant Advisory Committee (RTAC). A retrospective study of B-cell crossmatch with Luminex<sup>®</sup> technology in well-matched highly sensitized patients from the AUSTRALIAN interstate exchange. The 44<sup>th</sup> Annual Scientific Meeting of Australia and New Zealand Society of Nephrology (ANZSN) 6-10 September 2008, Newcastle, Australia.  
*Finalist for The Clinical Science Young Investigator Award*
11. Hooi Sian Eng, Greg Bennett, Eleni Tsiopelas, Sean Chang, Peter Bardy, Graeme Russ, P. Toby H. Coates. Alloantibody involvement and risk factors in transplant glomerulopathy. The 44<sup>th</sup> Annual Scientific Meeting of Australia and New Zealand Society of Nephrology (ANZSN) 6-10 September 2008, Newcastle, Australia.
12. Hooi Sian Eng, Scott Campbell, Graeme Russ, P. Toby H. Coates, Peter Bardy, Greg Bennett, Sean Chang, Brian Tait, On behalf of the Renal Transplant Advisory Committee (RTAC). Predictive value of B-cell crossmatch and Luminex<sup>®</sup> antibody analysis in well-matched highly sensitized patients from the Australian National Interstate Exchange (ANIE). The 34<sup>th</sup> Annual Meeting of American Society For Histocompatibility and Immunogenetics (ASHI) 27-31 October 2008, Toronto, Canada.
13. Hooi Sian Eng, Greg Bennett, Eleni Tsiopelas, Sean Chang, Peter Bardy, Graeme Russ, P. Toby H. Coates. Donor specific anti-HLA antibodies in transplant glomerulopathy. The 34<sup>th</sup> Annual Meeting of American Society For Histocompatibility and Immunogenetics (ASHI) 27-31 October 2008, Toronto, Canada.

## **xii. Awards**

1. Young Investigator Award of Amgen-The Transplantation Society of Australia and New Zealand. The 31<sup>st</sup> Annual Scientific Meeting, 28-30 March 2007, Canberra, Australia.
2. Kidney Health Australia For The Best Clinical Science Presentation Award. The 43<sup>rd</sup> Annual Scientific Meeting of The Australia and New Zealand Society of Nephrology (ANZSN) 8-12 September 2007, Queensland, Australia.
3. Top 10 Abstracts Young Investigation Award of The XXII International Congress of The Transplantation Society 10-14 August 2008, Sydney, Australia.
4. Young Investigator Award of Amgen-The Transplantation Society of Australia and New Zealand. The XXII International Congress of The Transplantation Society 10-14 August 2008, Sydney, Australia.
5. Young Investigator Award of The Transplantation Society of Australia and New Zealand. The XXII International Congress of The Transplantation Society 10-14 August 2008, Sydney, Australia.
6. Nominee for The President's Award of The Transplantation Society of Australia and New Zealand. The XXII International Congress of The Transplantation Society 10-14 August 2008, Sydney, Australia.
7. Finalist for The Clinical Science Young Investigator Award The 44<sup>th</sup> Annual Scientific Meeting of Australia and New Zealand Society of Nephrology (ANZSN) 6-10 September 2008, Newcastle, Australia.